Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada

Authors not listed

CanSino Biologics Inc. · 2020

Dysbiosis Human Randomized controlled trial

Abstract

This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to \<55 and 65 to \<85 years of age，with the randomized, observer-blind, dose-escalation design

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-01 MST

Cite this

APA

Anonymous. (2020). A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada. <em>CanSino Biologics Inc.</em>. https://clinicaltrials.gov/study/NCT04398147

Vancouver

Anonymous. A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada. CanSino Biologics Inc.. 2020.

BibTeX

@misc{anon2020ARando, title = {A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada}, author = {Anonymous}, journal = {CanSino Biologics Inc.}, year = {2020}, }